Adjuvant chemotherapy of bladder cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  Boccardo, F ^a,b   Palmeri, L ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Adjuvant therapy; Bladder cancer; Muscle invasive

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; CYSTECTOMY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; INFORMATION PROCESSING; LYMPH NODE METASTASIS; META ANALYSIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

EID: 33745609548     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj967     Document Type: Review

References (23)

1. Stein JP, Liekovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patents. J Clin Oncol 2001; 19: 666.
2. Loehrer PJ, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma. J Clin Oncol 1992; 10: 1066-1073.
3. Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1997; 15: 2564-2569.
4. Logothesis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8: 1050-1055.
5. Sternberg CN, Yagoda A, Scher HI et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelial: Efficacy and patterns of response and relapse. Cancer 1989; 64: 2448-2458.
6. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-3077.
7. Logothesis CJ, Johnson DE, Chong C et al. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: An update. J Clin Oncol 1988; 6: 1590-1596.
8. Michael M, Tannock IF, Czaykowski PM et al. Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: The Princess. Margaret Hospital experience. Br J Urol 1998; 82: 366-372.
9. Skinner DG, Daniels JR, Russel CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial. J Urol 1991; 145: 459-464.
10. Stockle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): Improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992; 148: 302.
11. Stockle M, Wellek S, Meyenburg W et al. Radical cystectomy with or without adjuvant polichemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: Prognostic impact of lymph node involvement. Urology 1996; 48: 868.
12. Richards B, Bastable JR, Freedman L et al. Adjuvant chemotherapy with doxorubicin (adriamycin) and 5-fluorouracil in T3, Nx, MO bladder cancer treated with radiotherapy. Br J Urol 1983; 55: 386-391.
13. Studer UE, Bacchi M, Biedermann C et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: A prospective comparative trial. J Urol 1994; 152: 81-84.
14. Bono AV, Benvenuti C, Gibba A et al. Adjuvant chemotherapy in locally advanced bladder cancer. Final analysis of a controlled multicentre study. Acta Urol Ital 1997; 11 (1): 5-8.
15. Otto T, Borgermann C, Krege S et al. Adjuvant chemotherapy in locally advanced bladder cancer (pT3/T4a, pN1-2, MO) a phase III study. Eur Urol 2001; 39: 147 (abstr 577).
16. Freiha F, Reese J and Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996; 155: 495.
17. Lehmann J, Retz M, Wiemers C et al. Adjuvant cisplatin plus methotrexate, versus methatrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: Results from a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol August 2005.
18. Sternberg CN. Neo-adjuvant and adjuvant chemotherapy of bladder cancer: is there a role? Ann Oncol 2002; 13 (S4): 273-279.
19. Juffs HG, Moore MJ and Tannock IF. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. The Lancet Oncology 2002; 3: 738-747.
20. Pectasides D, Pectasides M and Nikolaou M. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: Literature review. Eur Urol 2005; 48: 60-68.
21. Boyar M and Petrylak DP. Adjuvant chemotherapy for transitional cell carcinoma of the bladder: Paradigms for the design of clinical trials. Current Oncol Reports 2005; 7: 207-214.
22. Rosenberg JE, Carrol PR and Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol 2005; 174: 14-20.
23. The Advanced Bladder Cancer Meta-Analysis Collaboration. Adjuvant Chemotherapy in Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. Eur Urol 2005; 48: 202-216.